Evidence map›Paper›PMID 38659882›Full record

ArticlebioRxiv : the preprint server for biology2025

Circulating tumor cells shed shearosome extracellular vesicles in capillary bifurcations that activate endothelial and immune cells.

Angelos Vrynas, Salime Bazban-Shotorbani, Sara Arfan, Karishma Satia, Brian Cunningham, Gauhar Sagindykova, Mymuna Ashna, Aoyu Zhang, Diana Visan, Aisher Chen and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Angelos VrynasDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.
Salime Bazban-ShotorbaniDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.
Sara ArfanDivision of Molecular Pathology, The Institute of Cancer Research; London, SM2 5NG, United Kingdom.
Karishma SatiaCancer Research UK National Biomarker Centre, University of Manchester; Manchester, M13 9PL, United Kingdom.
Brian CunninghamDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.
Gauhar SagindykovaDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.
Mymuna AshnaDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.
Aoyu ZhangDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.
Diana VisanDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.
Aisher ChenDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.
Teige Matthews-PalmerDivision of Structural Biology, The Institute of Cancer Research (ICR); London, SW7 3RP, United Kingdom.
Mathew CarterCancer Research UK National Biomarker Centre, University of Manchester; Manchester, M13 9PL, United Kingdom.
Fiona BlackhallCancer Research UK Lung Cancer Centre of Excellence; Manchester, M13 9PL, United Kingdom.
Kathryn L SimpsonCancer Research UK National Biomarker Centre, University of Manchester; Manchester, M13 9PL, United Kingdom.
Caroline DiveCancer Research UK National Biomarker Centre, University of Manchester; Manchester, M13 9PL, United Kingdom.
Paul HuangDivision of Molecular Pathology, The Institute of Cancer Research; London, SM2 5NG, United Kingdom.
Sam H AuDepartment of Bioengineering, Imperial College London; London, SW7 2AZ, United Kingdom.

Funding

Coordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9M
Novel therapeutic development for small cell lung cancerR35CA263816 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Charles M. Rudin · 2021 to 2026
$6.3M
NCI NIH HHS R35 CA263816NCI NIH HHS U24 CA213274
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) and their clusters are the drivers of metastasis, but we have an incomplete understanding of how they interact with capillary beds. Using microfluidic models mimicking human capillary bifurcations, we observed cell size- and bifurcation-dependent shedding of nuclei-free fragments by patient CTCs, CTC-derived explant cells and numerous cancer cell lines. Shedding reduced cell sizes up to 61%, facilitating their transit through bifurcations. We demonstrated that shed fragments were a novel subclass of large extracellular vesicles (LEVs), "shearosomes", that require shear stress for their biogenesis and whose proteome was associated with immune-related pathways. Shearosomes exhibited functions characteristic of previously identified EVs including cell-directed internalization by endothelial and immune cells, and intercellular communication abilities such as disruption of endothelial barrier integrity, polarization of monocytes into M2 tumor-promoting macrophages and interactions between endothelial and immune cells. Cumulatively, these findings suggest that CTCs shed shearosomes in capillary beds that drive key processes involved in the formation of pre-metastatic niches.

Identifiers

PMID38659882
PMCPMC11042361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.